Get the latest Science News and Discoveries
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
None
Or read this on Eureka AlertGet the latest Science News and Discoveries
None
Or read this on Eureka AlertRead more on:
Related news: